NASDAQ · BRTX
Healthcare · Biotechnology
$1.40
Down-$0.18 (-11.37%)
Updated Nov 1, 2026, 5:58 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BRTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BRTX closed at $1.40 after 20 trading sessions, down 37.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.58 | $1.58 | $1.4001 | $1.4003 | 28.8K |
| Oct 29, 2026 | $1.44 | $1.65 | $1.39 | $1.58 | 233.64K |
| Oct 28, 2026 | $1.39 | $1.55 | $1.38 | $1.39 | 17.91K |
| Oct 27, 2026 | $1.53 | $1.54 | $1.36 | $1.36 | 8.69K |
| Oct 26, 2026 | $1.58 | $1.58 | $1.4501 | $1.58 | 35.01K |
| Oct 23, 2026 | $1.5033 | $1.65 | $1.40 | $1.62 | 34.96K |
| Oct 22, 2026 | $1.57 | $1.62 | $1.50 | $1.50 | 4.81K |
| Oct 21, 2026 | $1.58 | $1.58 | $1.51 | $1.53 | 13.24K |
| Oct 20, 2026 | $1.6184 | $1.65 | $1.54 | $1.56 | 16.52K |
| Oct 19, 2026 | $1.51 | $1.67 | $1.51 | $1.60 | 18.49K |
| Oct 16, 2026 | $1.53 | $1.55 | $1.49 | $1.54 | 21.01K |
| Oct 15, 2026 | $1.50 | $1.50 | $1.28 | $1.46 | 27.94K |
| Oct 14, 2026 | $1.50 | $1.56 | $1.4201 | $1.50 | 18.43K |
| Oct 13, 2026 | $1.70 | $1.71 | $1.4386 | $1.59 | 32.42K |
| Oct 12, 2026 | $1.85 | $1.90 | $1.7046 | $1.75 | 11.35K |
| Oct 9, 2026 | $1.92 | $1.95 | $1.85 | $1.91 | 18.44K |
| Oct 8, 2026 | $2.18 | $2.18 | $1.7501 | $1.89 | 95.9K |
| Oct 7, 2026 | $2.30 | $2.30 | $2.05 | $2.24 | 38.68K |
| Oct 6, 2026 | $2.20 | $2.2895 | $2.135 | $2.27 | 79.66K |
| Oct 5, 2026 | $2.16 | $2.305 | $2.0096 | $2.24 | 85.22K |
The latest Smart Investors Daily articles mentioning BRTX.
Company
Market Activity
Research & News
BRTX research
Company profile and research snapshot.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Maxim Group | Hold | — |
| Aug 14, 2024 | Roth MKM | Buy | — |
| Jun 12, 2024 | Roth MKM | Buy | — |
| Aug 14, 2023 | Roth MKM | Buy | — |
| Dec 7, 2022 | Roth Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 8, 2026
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock moved
ChartMill · Feb 25, 2026
Which stocks have an unusual volume on Wednesday?
ChartMill · Feb 25, 2026
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Benzinga · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRTX.
